[go: up one dir, main page]

NO20051181L - Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering - Google Patents

Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering

Info

Publication number
NO20051181L
NO20051181L NO20051181A NO20051181A NO20051181L NO 20051181 L NO20051181 L NO 20051181L NO 20051181 A NO20051181 A NO 20051181A NO 20051181 A NO20051181 A NO 20051181A NO 20051181 L NO20051181 L NO 20051181L
Authority
NO
Norway
Prior art keywords
molecular weight
high molecular
preparing
hyaluronic acid
weight hyaluronic
Prior art date
Application number
NO20051181A
Other languages
English (en)
Other versions
NO334523B1 (no
Inventor
Stefano Carlino
Original Assignee
Medidom Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31502852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051181(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medidom Lab filed Critical Medidom Lab
Publication of NO20051181L publication Critical patent/NO20051181L/no
Publication of NO334523B1 publication Critical patent/NO334523B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

En fremgangsmåte for å fremstille en steril bruksklar vandig farmasøytisk formulering som omfatter et høymolekylvekts hyaluronsyresalt (HA) ved en spesifisert konsentrasjon, omfatter trinnene: å fremskaffe en vandig formulering omfattende høymolekylvekts-HA ved en konsentrasjon som er mindre enn den spesifiserte sluttkonsentrasjon; passere nevnte vandige formulering gjennom et filter som har en porestørrelse som er mindre enn 45 føn; konsentrere nevnte vandige formulering ved å tilføre et vakuum og koke av vann inntil nevnte spesifiserte konsentrasjon blir nådd.
NO20051181A 2002-08-07 2005-03-04 Fremgangsmåte for fremstilling av en steril høy molekylærvekts hyaluronsyreformulering NO334523B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02405681 2002-08-07
PCT/IB2003/003524 WO2004014399A1 (en) 2002-08-07 2003-08-04 Process for preparing a sterile high molecular weight hyaluronic acid formulation

Publications (2)

Publication Number Publication Date
NO20051181L true NO20051181L (no) 2005-05-06
NO334523B1 NO334523B1 (no) 2014-03-31

Family

ID=31502852

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051181A NO334523B1 (no) 2002-08-07 2005-03-04 Fremgangsmåte for fremstilling av en steril høy molekylærvekts hyaluronsyreformulering

Country Status (20)

Country Link
US (1) US7939655B2 (no)
EP (1) EP1526859B1 (no)
JP (1) JP4597672B2 (no)
KR (1) KR101169473B1 (no)
CN (1) CN100366296C (no)
AU (1) AU2003255892B2 (no)
BR (1) BRPI0312669B8 (no)
CA (1) CA2492739C (no)
DK (1) DK1526859T3 (no)
ES (1) ES2397382T3 (no)
HR (1) HRP20041230B1 (no)
IL (1) IL166231A (no)
MX (1) MXPA05000533A (no)
NO (1) NO334523B1 (no)
NZ (1) NZ538019A (no)
PL (1) PL217885B1 (no)
PT (1) PT1526859E (no)
SI (1) SI1526859T1 (no)
WO (1) WO2004014399A1 (no)
ZA (1) ZA200500259B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326883C (zh) * 2005-11-04 2007-07-18 山东福瑞达生物化工有限公司 一种透明质酸钙的制备方法
CN100478360C (zh) * 2006-10-31 2009-04-15 山东福瑞达生物化工有限公司 将浓缩用于透明质酸或其盐的生产的方法
EP2209814B1 (en) 2007-11-13 2017-01-25 Bio-Technology General (Israel) Ltd. Dilute filtration sterilization process for viscoelastic biopolymers
KR101449687B1 (ko) * 2008-03-13 2014-10-14 주식회사 바이오랜드 저분자 및 고분자 히알루론산과 유근피로부터 분리된다당체 추출물을 함유하는 노화방지용 조성물
US8283463B2 (en) * 2010-02-09 2012-10-09 Bausch & Lomb Incorporated Sterile hyaluronic acid solutions
KR101379930B1 (ko) * 2011-12-12 2014-04-14 가톨릭대학교 산학협력단 후발성 백내장 억제용 조성물 및 이의 제조 방법
AU2019218711B2 (en) 2018-02-06 2024-12-05 Regen Lab Sa Cross-linked hyaluronic acids and combinations with PRP/BMC
CN112714644B (zh) * 2018-09-20 2024-03-29 香港科技大学 滴眼剂组合物
WO2020057606A1 (en) * 2018-09-20 2020-03-26 The Hong Kong University Of Science And Technology Eyedrop compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US5093487A (en) 1986-01-06 1992-03-03 Mobay Corporation Low viscosity high molecular weight filter sterilizable hyaluronic acid
JP2893451B2 (ja) * 1988-08-09 1999-05-24 昭和産業株式会社 高分子量のヒアルロン酸を製造する方法
IT1251151B (it) * 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
IT1259090B (it) 1992-04-17 1996-03-11 Fidia Spa Biomaterialli per protesi d'osso
JP2844296B2 (ja) * 1993-06-29 1999-01-06 正樹 佐久間 真空濃縮装置
CN1064372C (zh) * 1994-08-26 2001-04-11 顾其胜 透明质酸钠制剂的制备方法
KR19980080116A (ko) 1997-03-27 1998-11-25 히라따 다다시 히알루론산 나트륨의 정제법
CH692919A5 (fr) * 1999-01-28 2002-12-13 Trb Chemedica S A Procédé de purification de l'acide hyaluronique à poids moléculaire élevé.
US6660853B2 (en) * 2000-12-15 2003-12-09 Al Prescott Method for purifying high molecular weight hyaluronic acid
EP1217008B1 (en) 2000-12-19 2006-03-01 Seikagaku Corporation Photocurable hyaluronic acid derivative and process for producing the same, and photocured crosslinked hyaluronic acid derivative and medical material using the same

Also Published As

Publication number Publication date
PL373893A1 (en) 2005-09-19
KR101169473B1 (ko) 2012-07-30
PT1526859E (pt) 2013-01-25
US7939655B2 (en) 2011-05-10
HK1080715A1 (zh) 2006-05-04
AU2003255892B2 (en) 2008-02-21
BRPI0312669B1 (pt) 2015-08-11
IL166231A0 (en) 2006-01-15
JP4597672B2 (ja) 2010-12-15
CN100366296C (zh) 2008-02-06
ZA200500259B (en) 2005-12-28
HRP20041230B1 (hr) 2013-02-28
EP1526859B1 (en) 2012-10-24
NZ538019A (en) 2006-02-24
CA2492739A1 (en) 2004-02-19
BRPI0312669B8 (pt) 2021-05-25
PL217885B1 (pl) 2014-08-29
MXPA05000533A (es) 2005-04-19
EP1526859A1 (en) 2005-05-04
HRP20041230A2 (en) 2005-06-30
US20060052336A1 (en) 2006-03-09
BR0312669A (pt) 2005-04-26
JP2005536530A (ja) 2005-12-02
DK1526859T3 (da) 2013-02-04
IL166231A (en) 2011-10-31
AU2003255892A1 (en) 2004-02-25
KR20050044900A (ko) 2005-05-13
NO334523B1 (no) 2014-03-31
WO2004014399A1 (en) 2004-02-19
SI1526859T1 (sl) 2013-01-31
ES2397382T3 (es) 2013-03-06
CA2492739C (en) 2011-05-31
CN1674920A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO924873L (no) Fremgangsmaate til rensing av hyaluronsyre og fraksjon av ren hyaluronsyre til oftalmologisk anvendelse
NO985821L (no) Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer
NO20051181L (no) Fremgangsmate for fremstilling av en steril hoy molekylaervekts hyaluronsyreformulering
NO20091168L (no) Hoyselektive reopptaksinhibitorer for norepinefrin
ATE499121T1 (de) Viskoelastische lösungen mit natriumhyaluronat und hydroxypropylmethylcellulose, herstellung und verwendungen
CA2535364A1 (en) Hyaluronic acid nanoparticles
ATE544445T1 (de) Herstellung von sterilen wässrigen suspensionen mit mikronisierten kristallinen wirkstoffen zur inhalation
RU2007122392A (ru) Водная офтальмологическая суспензия кристаллического ребамипида
NO20061674L (no) Sterilisering ved hoyt trykk for avsluttende sterilisering av farmasoytiske preparater og medisinske produkter
PL362667A1 (en) Novel amlodipine camsylate and method for preparing thereof
NO20072089L (no) Benzimidazolderivater, sammensetninger som inneholder dem, fremstilling derav og anvendelse derav
AU3070400A (en) Process for purifying high molecular weight hyaluronic acid
DK1663141T3 (da) Vandig farmaceutisk oplösning indeholdende oxymetazolin og/eller xylometazolin
ATE428730T1 (de) Verfahren zur herstellung einer alpha-1- antitrypsinlösung
EP1609473A8 (en) Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria
NO20061417L (no) Syreinneholdende oxaliplatinformuleringer
NO20050529L (no) Ciclesonidinneholdende steril vandig suspensjon
DK1248768T3 (da) Substituerede acylguanidiner, fremgangsmåde til deres fremstilling, deres anvendelse som medikamenter eller diagnostika samt medikamenter, der indeholder disse
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
SE0102057D0 (sv) New Salts I
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
RU1803110C (ru) Способ получени глазных капель
WO2004043486A8 (en) An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism
WO1997024374A1 (fr) Solution stable contenant du hyaluronate de sodium

Legal Events

Date Code Title Description
MK1K Patent expired